T300A GENETIC POLYMORPHISM: a susceptibility factor for Crohn’s disease?

Scolaro, Bruno Lorenzo; Santos, Emily dos; Ferreira, Leslie Ecker; França, Paulo Henrique Condeixa de; Kleinubing, Harry; Kotze, Paulo Gustavo; Pinho, Mauro

doi:10.1590/s0004-28032014000200005

Cited by 5 publications

(2 citation statements)

References 18 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 843 potentially relevant articles were initially identified. After exclusion of duplicate studies and application of the inclusion criteria, a total of 44 articles 12 – 55 were included in the qualitative synthesis ( Figure 1 ). Büning et al.…”

Section: Resultsmentioning

confidence: 99%

Association between ATG16L1 gene polymorphism and the risk of Crohn’s disease

Zhang

Yang

et al. 2016

J Int Med Res

View full text Add to dashboard Cite

ObjectiveTo perform a meta-analysis to evaluate studies investigating the association between ATG16L1 gene polymorphism and Crohn’s disease.MethodsPubMed, Embase and Web of Science databases were searched for all studies focusing on the association of ATG16L1 and Crohn’s disease. Combined odds ratios with 95% confidence intervals were calculated for four genetic models (allelic model: G allele versus A allele; additive model: GG versus AA; dominant model: GA + GG versus AA; recessive model: GG versus GA + AA) using either a random effects or fixed effects model.ResultsA total of 47 case–control studies involving 18 638 cases and 30 181 controls were included in the final meta-analysis. There was a significant association between ATG16L1 and Crohn’s disease for all four genetic models. Significant associations were also shown in subgroup analyses when stratified by study design (population- or hospital-based).ConclusionIn this meta-analysis, the ATG16L1 genotype was significantly associated with the risk of developing Crohn’s disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Association between ATG16L1 gene polymorphism and the risk of Crohn’s disease

Zhang

Yang

et al. 2016

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…The ATG16L1 gene is located on chromosome 2 and encodes a protein related to autophagy processes. It has been observed that defects in this gene can cause susceptibility to inflammatory bowel disease (36).…”

Section: Atg16l1mentioning

confidence: 99%

Pharmacogenetic biomarkers of response in Crohn’s disease

et al. 2017

View full text Add to dashboard Cite

Crohn's disease (CD) is a chronic condition, which affects the immune system. It can also affect any part of the digestive tract and be associated with external manifestations. The causes of the disease remain unknown, although it seems to be the result of a combination of factors, such as genetic predisposition, environment, lifestyle and the composition of the microbiota, among others. The treatment protocol begins with a change in eating and smoking habits, and is continued with different lines of treatment, including corticosteroids, immunomodulators and biologic therapy (infliximab and adalimumab), which have shown differences in response among patients, especially with biologic treatment. Several studies have considered the possibility that these differences in response are caused by the genetic variability of patients. Many genes have been investigated as potential predictors of response to biological drugs, such as ADAM17, ATG16L1, EMSY, CASP9, CCNY, CNTN5, FASLG, FCGR, NOD2, PTGER4, IL13, IL1B, IL27, IL11, IL17F, TNF and TNFR genes. In this review, we will gather the information on influence of gene polymorphisms investigated to date on response to biological drugs in CD patients.

show abstract